MiniMed Group (NASDAQ:MMED) Now Covered by Analysts at Evercore

Evercore began coverage on shares of MiniMed Group (NASDAQ:MMED) in a report released on Tuesday morning, Marketbeat reports. The firm issued an outperform rating and a $20.00 target price on the stock.

Several other analysts have also recently commented on MMED. Citigroup assumed coverage on shares of MiniMed Group in a research note on Tuesday. They set a “buy” rating and a $23.00 price objective for the company. Morgan Stanley assumed coverage on shares of MiniMed Group in a report on Tuesday. They set an “overweight” rating and a $19.00 target price for the company. Bank of America assumed coverage on shares of MiniMed Group in a research report on Tuesday. They set a “buy” rating and a $27.00 target price for the company. Mizuho assumed coverage on shares of MiniMed Group in a report on Tuesday. They issued an “outperform” rating and a $21.00 price target on the stock. Finally, BTIG Research assumed coverage on MiniMed Group in a research note on Tuesday. They set a “buy” rating and a $25.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, MiniMed Group currently has a consensus rating of “Moderate Buy” and an average target price of $22.10.

MiniMed Group Stock Up 4.0%

Shares of NASDAQ MMED opened at $14.92 on Tuesday. MiniMed Group has a 52 week low of $14.10 and a 52 week high of $20.48.

More MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Multiple major brokerages initiated coverage with bullish ratings and high price targets, supporting upside expectations — notable examples include Bank of America ($27 PT) and Goldman Sachs ($24 PT). This broad coverage is being read as validation of MMED’s standalone pipeline and commercial opportunity. MiniMed initiated with ‘Buy’ rating by Bank of America on pipeline-driven growth outlook
• Positive Sentiment: Other buy/overweight/outperform starts include Wells Fargo ($26), BTIG ($25), Citigroup ($23), Mizuho ($21), Evercore ($20), Deutsche Bank ($20) and Morgan Stanley ($19) — analyst price targets span roughly $16–$27, implying material upside from recent levels and giving investors multiple bullish third‑party valuations. Coverage roundup
• Neutral Sentiment: Piper Sandler placed a neutral/”neutral” stance with a $16 price target — this is less bullish than many peers and may moderate expectations for near‑term re‑rating. Piper Sandler coverage note
• Negative Sentiment: Analysts who stayed cautious (Piper Sandler / coverage summarized on TipRanks) cite execution risks as a reason for a Hold/neutral view; those execution concerns could cap upside if the company misses early standalone milestones. Balancing Franchise Strength with Execution Risks: Why MiniMed Merits a Hold Rating

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.